Infectious Diseases

At IDWeek 2023, a White House expert on Mpox discusses initial reactions to the outbreak, vaccination rates, and where we need to do better in combatting this infectious disease.

At IDWeek 2023, a presentation on the latest recommendations for screening and management of hepatitis C in the pediatric population.

At a plenary session at IDWeek 2023, the benefits and challenges of using AI in treating infectious diseases was discussed.

New immunizations for RSV are making this respiratory infection preventable in ways it never was before. Here is the latest news on recent approvals and future outlooks.

A look at recent approvals and promising clinical trials for future vaccines.

As we head into cold and flu season, researchers try to answer the question of what physical interventions are best for infection prevention.

A refresher on best interventions for common respiratory disorders in children.

Due to increased RSV activity observed in Southeastern regions of the United States, the Centers for Disease Control and Prevention (CDC) has issued an official Health Alert Network Health Advisory. The CDC recommends that clinicians prepare to implement recently FDA-approved prevention methods.

Approved for use at 32 weeks through 36 weeks gestation, Pfizer’s maternal respiratory syncytial vaccine (Abrysvo), is delivered through a single dose injection to the muscle, and is the first vaccine for use in pregnant individuals to prevent lower respiratory tract disease (LRTD) and severe LRTD because of RSV in infants (birth to 6 months).

Basis for a Biologics License Application submission to the FDA is being built for PXVX0317, following topline results demonstrated in a pair of phase 3 trials, including 1 trial featuring adolescents and adults aged 12 to 64 years.

As children get ready to return to school, pediatric health care providers may start seeing more of this condition in their offices. Here is what you should know.

Previously available under an Emergency Use Authorization, the combination test can detect and distinguish COVID-19, influenza A/B, and respiratory syncytial virus (RSV). The clearance comes ahead of respiratory season, which, according to BD, could result in another “tripledemic” threat.

Ervebo has been approved by the FDA to prevent the Ebola virus for individuals aged 12 months and older, after being initially approved for those 18 years and older in 2019.

Prevention and treatment strategies for tick-borne diseases and respiratory infections

Expanding peripartum prophylaxis could be more cost-effective, but would likely lead to significant over-treatment.

Investigators studied 2 infants experiencing seizures, small head size, and developmental delays born of mothers who had contracted COVID-19 during pregnancy.

These findings suggest the World Health Organization's definition of post-COVID-19 condition (long COVID) may be too broad.

Children exposed to maternal COVID-19 during pregnancy showed lower birth weight, lower birth BMI, and accelerated postnatal weight gain, compared with those unexposed.

In a recent study, female offspring of mothers with a positive COVID-19 test during pregnancy were at a decreased risk of developing neurodevelopmental disorders compared to male offspring.

New maternal vaccine options could offer extra protection in upcoming seasons.

Exposure to a common seasonal coronavirus stimulates a memory T cell response that protects children against COVID-19. However, this immune response peaks at age 6.

If approved by the FDA, this 5-in-1 investigational candidate could provide the broadest meningococcal serogroup coverage.

At the 44th National Association of Pediatric Nurse Practitioners Conference, data was presented on the effectiveness of vaccines and antivirals in preventing life threatening conditions.

Assessing your knowledge of and performance on preventable diseases.

The Omicron variant caused the most symptoms in pediatric patients. However, there were no differences in adverse outcomes by COVID-19 variant.

Children were hospitalized the most during the Omicron variant, but disease outcomes were the least severe during this variant period.

The federal agency set a Prescription Drug User Fee Act (PDUFA) action date of August 2023.

In a recent analysis, worse maternal and neonatal outcomes were found when mothers were infected with COVID-19 close to delivery.

A recent grant awarded to Ann & Robert H. Lurie Children's Hospital of Chicago will look at the severity score of emergency department (ED)-based pediatric community-acquired pneumonia.

To address the increased demand for fever-reducing medications, the FDA has updated its compounding guidelines for licensed pharmacies, hospitals, and health systems.